Skip to main content
Erschienen in: Supportive Care in Cancer 2/2015

01.02.2015 | Original Article

Improving hospital performance in the treatment of febrile neutropenia

verfasst von: Barry Meisenberg, Jan Clemons, John Ness, Nancy Faust, Mary Clance

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Febrile neutropenia (FN) remains a common and dangerous complication of cancer treatment. Guidelines from the Infectious Disease Society of America urge initiating antibiotics within 2 h of presentation. We reviewed our institution’s performance to identify areas of needed improvement and to design performance improvement steps.

Methods

FN management was deconstructed into discrete tasks. Experienced practitioners estimated appropriate time allowance for each task. Cycle time analysis data on a baseline cohort (baseline group) identified causes and loci of delay. Based on these data, new processes to bypass roadblocks for timely therapy were introduced. Performance monitoring continued as these changes were implemented (the transitional group) and for 20 months thereafter (the post-intervention group).

Results

Sixty-nine episodes of FN were identified. Ten distinct improvement steps were implemented. Median time to antibiotics was reduced from 252 min, to 188 min and 118 min for the baseline, transitional, and post-intervention groups, respectively (p = 0.0002 for the baseline vs. the post-intervention group comparison). Variability was reduced with the inter-quartile range falling from 174 min (baseline) to 65 min (post-intervention). Despite improvement, there were persisting episodes of delays, due to competing priorities from other patients or decisions to postpone infusion of antibiotics until patients had been admitted. Standardized order sets eliminated improper antibiotic choices as a source of error.

Conclusions

Improvements in the management of FN can be accomplished and sustained by the focused study of performance of individual tasks, the design of streamlined processes by practitioners, and the ongoing review of performance with feedback to clinical departments.
Literatur
1.
Zurück zum Zitat Caggiano V, Weiss RV, Rickert TW, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924PubMedCrossRef Caggiano V, Weiss RV, Rickert TW, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924PubMedCrossRef
2.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266PubMedCrossRef Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266PubMedCrossRef
3.
Zurück zum Zitat Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed
4.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer; 2010 update by the Infectious Disease Society of America. Clin Infect Dis 52(4):e56–e93PubMedCrossRef Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer; 2010 update by the Infectious Disease Society of America. Clin Infect Dis 52(4):e56–e93PubMedCrossRef
5.
Zurück zum Zitat Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRef Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRef
6.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for indentifying low-risk febrile neutropenic patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for indentifying low-risk febrile neutropenic patients. J Clin Oncol 18:3038–3051PubMed
7.
Zurück zum Zitat Clarke RT, Warnick J, Stretton K, Littlewood TJ (2011) Improving the immediate management of neutropenic sepsis in the UK: lessons form a national audit. Brit J Haematol 153:773–779CrossRef Clarke RT, Warnick J, Stretton K, Littlewood TJ (2011) Improving the immediate management of neutropenic sepsis in the UK: lessons form a national audit. Brit J Haematol 153:773–779CrossRef
8.
Zurück zum Zitat Burry E, Punnet A, Mehta A, Thull-Freedman J, Robinson L, Gupta S (2012) Identification of Educational and infrastructural barriers to prompt antibiotic delivery in febrile neutropenia: a quality improvement initiative. Pediatr Blood Cancer 59:431–435PubMedCrossRef Burry E, Punnet A, Mehta A, Thull-Freedman J, Robinson L, Gupta S (2012) Identification of Educational and infrastructural barriers to prompt antibiotic delivery in febrile neutropenia: a quality improvement initiative. Pediatr Blood Cancer 59:431–435PubMedCrossRef
9.
Zurück zum Zitat Szwajcer D, Czaykowski P, Turner D (2011) Assessment and management of febrile neutropenia in emergency departments within a regional health authority-a benchmark analysis. Curr Oncol 18:280–284PubMedCentralPubMedCrossRef Szwajcer D, Czaykowski P, Turner D (2011) Assessment and management of febrile neutropenia in emergency departments within a regional health authority-a benchmark analysis. Curr Oncol 18:280–284PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Nirenberg A, Mulhearn L, Lin S, Larson E (2004) Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study. Oncol Nurs Forum 31:711–715PubMedCrossRef Nirenberg A, Mulhearn L, Lin S, Larson E (2004) Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study. Oncol Nurs Forum 31:711–715PubMedCrossRef
11.
Zurück zum Zitat Wu AW, Kipshutz AKM, Pronovost PJ (2008) Effectiveness and efficiency of root cause analysis in medicine. JAMA 299:685–687PubMedCrossRef Wu AW, Kipshutz AKM, Pronovost PJ (2008) Effectiveness and efficiency of root cause analysis in medicine. JAMA 299:685–687PubMedCrossRef
12.
Zurück zum Zitat Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA (2008) Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 87:139–145PubMedCrossRef Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA (2008) Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 87:139–145PubMedCrossRef
13.
Zurück zum Zitat Baltic T, Schlosser E, Bedell MK (2002) Neutropenic fever: one institution’s quality improvement project to decease time from patient arrival to initiation of antibiotic therapy. Clin J Oncol Nurs 6:337–340PubMedCrossRef Baltic T, Schlosser E, Bedell MK (2002) Neutropenic fever: one institution’s quality improvement project to decease time from patient arrival to initiation of antibiotic therapy. Clin J Oncol Nurs 6:337–340PubMedCrossRef
Metadaten
Titel
Improving hospital performance in the treatment of febrile neutropenia
verfasst von
Barry Meisenberg
Jan Clemons
John Ness
Nancy Faust
Mary Clance
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2377-y

Weitere Artikel der Ausgabe 2/2015

Supportive Care in Cancer 2/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.